Immunocore Holdings Plc - Company Profile

Powered by

All the data and insights you need on Immunocore Holdings Plc in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Immunocore Holdings Plc Strategy Report

  • Understand Immunocore Holdings Plc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Immunocore Holdings Plc: Overview

Select Item

Related keylists

Immunocore Holdings Plc (Immunocore) is a biotechnology company that- focuses on the development of immunotherapeutic drugs for the treatment of cancer, infectious diseases, and autoimmune diseases. The company develops its drugs using proprietary T cell receptor (TCR) technology. Its products under development include IMC-C103C, IMC-F106C, IMC-I109V, IMC-M113V and IMCgp100. The company works in collaboration with various pharmaceutical companies, to develop its product candidates for the treatment of metastatic cutaneous melanoma; cancer; and other indications. It has presence in the UK, the US, Australia, New Zealand and Asia, Europe. Immunocore is headquartered in Oxfordshire, the UK.

 Gain a 360-degree view of Immunocore Holdings Plc and make more informed decisions for your business Gain a 360-degree view of Immunocore Holdings Plc and make more informed decisions for your business Find out more
Headquarters United Kingdom
Address 90 Park Drive, Milton Park, Abingdon, England, OX144RY
Website www.immunocore.com
Telephone 44 1235 438600
No of Employees 497
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange IMCR (NASD)
Revenue (2022) $249.4M 43.1% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -5.2% (2022 vs 2021)
Market Cap* $2.8B
Net Profit Margin (2022) XYZ 26.4% (2022 vs 2021)
* As of and is in US$
View Immunocore Holdings Plc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Immunocore Holdings Plc premium industry data and analytics

70+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Immunocore Holdings Plc’s relevant decision makers and contact details.

40+

Catalyst Calendar

Proactively evaluate Immunocore Holdings Plc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Pipeline Drugs

Identify which of Immunocore Holdings Plc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

17+

Clinical Trials

Determine Immunocore Holdings Plc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

5

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Marketed Drugs

Understand Immunocore Holdings Plc’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Immunocore Holdings Plc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
KIMMTRAK (tebentafusp-tebn) Immunocore
Pipeline ImmTAC
Oncology: ImmTAX
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Immunocore Holdings Plc portfolio and identify potential areas for collaboration Understand Immunocore Holdings Plc portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters Immunocore Holdings Plc Gilead Sciences Inc Regeneron Pharmaceuticals Inc BioNTech SE Gritstone Bio Inc
Headquarters United Kingdom United States of America United States of America Germany United States of America
City Abingdon Foster City Tarrytown Mainz Emeryville
State/Province England California New York Nordrhein-Westfalen California
No. of Employees 497 18,000 13,450 6,133 231
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
John Bell Chairman Executive Board 2015 70
Bahija Jallal, Ph.D Chief Executive Officer; Director Executive Board 2019 61
Brian Di Donato Head - Strategy; Chief Financial Officer Senior Management 2020 56
Annelise Vuidepot, PhD Chief Technology Officer; Head - Pipeline and Platform Research Senior Management - -
Amy Judge-Prein Chief Compliance Officer Senior Management 2021 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Immunocore Holdings Plc key executives to enhance your sales strategy Gain insight into Immunocore Holdings Plc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward